



# AV Therapeutics Inc. (OTCQB: AVTH)

January 21, 2015  
Recent Price: \$0.03

## Market Data

Fiscal Year	December 31
Industry	Biotechnology
Market Cap	\$2.5M
Insider Ownership	61.1%
Shares Outstanding	81.9M
Float	31.8M
Avg. Daily Vol. (3 mos.)	84,645
<i>As of January 20, 2015</i>	

## Income Snapshot

TTM

Operating Income	(\$1.7M)
Net income	(\$1.7M)

## Balance Sheet Snapshot

MRQ

Cash	\$0.3M
Debt	\$0.3M

## Auditor

Marcum LLP

## Legal Counsel

Sichenzia Ross Friedman Ference  
LLP

## Company Overview

AV Therapeutics, Inc. is engaged in the business of developing cancer therapeutics and immunotherapeutic vaccines that can be used alone or in combination with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. The Company's immune-therapeutics is based on the ability of certain proprietary reagents to re-educate or reprogram an immune system that can target previously unidentified micro-metastases. The Company intends to clinically develop both of these approaches for metastatic and early-stage prostate cancer.

## Value Proposition

AV Therapeutics has identified and patented a chemo therapeutic drug called Capridine that has shown in preclinical models to have specific activity against prostate and colon cancer. This drug is expected to be the frontline AV Therapeutics product specifically in prostate cancer where limited chemotherapy exists at present. More than \$6 million has been invested in the development of Capridine, including funding by the National Institutes of Health and the Department of Defense. The Company is expected to enter Phase I trials for Capridine in 2015.

## Investment Highlights

- Scientists at AVT have developed Capridine, a patented drug having specific activity against prostate cancer
- Initially targeting metastatic and early-stage prostate cancer
- Outstanding physicians and clinical researchers, including internationally recognized, well published scientists and clinicians (PhD's and MDs) from A+ institutions
- Capridine addresses a \$2 billion market for treatment of prostate cancer
- US patent on combination of Capridines with other agents
- GMP synthesis has been completed on Capridine
- National Cancer Institute tested prostate cancer specific drug
- Over 6 million dollars invested in development (pre-AVT), including funding from the National Institutes of Health and the Department of Defense

## Phase 1 Clinical Trial Consortium

Phase 1 clinical trials will be performed at leading cancer centers.



Advanced  
Vaccine  
Therapeutics